MindBio Therapeutics Corp. announced it has received its first batch of MB22001 ready for take-home use in Phase 2 psychedelic microdosing clinical trials. MB22001 is a proprietary titratable form of Lysergic Acid Diethylamide (LSD) designed for safe and effective take home microdosing in patients suffering from Major Depressive Disorder.

Ethics Committee approval and Clinical Trials Registry approvals have already been received. Dosing in the first cohort of clinical trial participants is expected to begin shortly after final ministerial approvals are received. MindBio's LSD-Microdosing clinical trials to date have yielded positive top line data such as improved quality of sleep including REM and total time of sleep and statistically significant enhancements in subjective feelings of "wellness", "creativity", "h happiness", " social connectivity" and "energy".

Participants in the LSD-Microdosing group also reported statistically significant feelings of being less "angry" and less "irritable". The data collected from the trial adds to MindBio's intellectual property in a Big Data play for the Company. MindBio is working towards the commercialization of microdosing treatments with a package of proprietary solutions for safe and effective at home use of psychedelics.

MindBio remains the only organization in the world approved for take-home use of LSD-Microdosing in clinical trials. The take home approvals are vital for testing the ecological validity of MindBio's proprietary solutions as the Company progresses its commercialization strategy for global regulatory approvals. MindBio has two fully funded Phase 2 LSD-Microdosing clinical trial starting shortly.

The first trial focuses on Major Depressive Disorder, where 20 patients meeting DSM-V criteria will receive an open label 8-week LSD microdosing treatment regimen in a naturalistic at-home setting. This trial will serve as the basis for continuing a much larger Phase 2b triple-dummy, active placebo-controlled trial in depressed patients. MindBio's investment thesis, using microdosing, centers on the creation of a unique treatment model that is globally scalable, safe, accessible, and affordable, aiming to address the existing challenges in mental health care and also caters for the diversity of medical regulatory regimes around the world.